|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||29.25 - 29.51|
|52 Week Range||26.30 - 32.42|
|PE Ratio (TTM)||23.28|
|Forward Dividend & Yield||1.08 (3.84%)|
|1y Target Est||N/A|
European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.
Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.
Like a growing number of its peers, Roche Holding AG pledged this week not to raise drug prices for the rest of the year. Roche gave the U.S. government its no-price-rises promise on July 11, the company said in a statement Friday. The health system also needs to focus on “long-term, system-wide solutions that lower costs,” Roche said.
European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
The U.S. Food and Drug Administration has granted Roche an accelerated review for its Elecsys product used to diagnose Alzheimer's disease, the Swiss drugmaker said on Friday. The FDA gave breakthrough ...
Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).
Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
Japan's Nikkei share average soared to a more than one-month high on Wednesday morning as exporters such as automakers and technology firms got a boost after the dollar hit a six-month high against the ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.
Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. Some analysts, however, have only muted expectations for the drug, baloxavir marboxil, since previously published results showed modest benefit compared to Roche's older Tamiflu medicine that is already under pressure from cheaper copies. In severe flu outbreaks, millions of people can get sick, resulting in hospital treatment and potentially hundreds of thousands of deaths, in particular among older people or those with compromised immune systems.
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.
U.S. President Donald Trump exulted this week over Pfizer Inc.’s decision to delay planned drug price increases a day after he attacked the company on Twitter. He should take a look at China, where President Xi Jinping has done much better.
An emerging wave of blockbuster drugs will accelerate European pharmaceutical companies' revenue growth into 2019, says Moody's Investors Service in a report published today. The rating agency's report is an update to the markets and does not constitute a rating action.
A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.
China has vowed to speed up cuts to the cost of cancer drugs in a move that threatens to dent revenues in the country for multinationals such as Eli Lilly, Roche and Novartis. Officials will “accelerate price cuts” for cancer treatments, the Communist party-run People’s Daily reported over the weekend.
Biogen BIIB and partner Eisai announced that amyloid antibody BAN2401 has yielded positive data in a large Phase 2 study in Alzheimer's disease. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan).
For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales. This is the story of Alzheimer’s. Dramatic ups and downs have been typical, with about 200 failed attempts to find a treatment. Drugmakers are seeking to escape a maze, trying one approach, failing, then starting over with another.
Let's put Roche Holding (RHHBY) stock into this equation and find out if it is a good choice for value-oriented investors right now.
ZURICH (Reuters) - Swiss private bank Vontobel (VONN.S) could cut up to a third of the workforce at Notenstein La Roche after it completed the takeover of its smaller rival. Vontobel could cut up to 140 ...
Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.